Immunotherapy drug could boost cervical cancer treatment

NCT ID NCT07168200

Recruiting now Disease control Sponsor: Shanghai Shengdi Pharmaceutical Co., Ltd Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This phase 3 trial tests whether adding the immunotherapy drug adebrelimab to standard chemoradiotherapy helps people with locally advanced cervical cancer live longer without their cancer getting worse. About 720 participants will receive either adebrelimab or a placebo alongside their usual treatment. The study is currently recruiting.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Adebrelimab (an immunotherapy drug) combined with chemotherapy (cisplatin, carboplatin, paclitaxel) and radiation
What this could lead to: If successful, this could offer a new standard treatment that delays cancer progression in people with locally advanced cervical cancer.
What could go wrong: This is a phase 3 trial, but results are not yet known. Immunotherapy can cause immune-related side effects, and the added benefit over standard chemoradiotherapy is unproven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED CERVICAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cervical cancer cervical carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED CERVICAL CANCER

Contacts and locations

Locations

Fudan University Shanghai Cancer Center
RECRUITING

Shanghai, Shanghai Municipality, 200032, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.